Vaccination strategy equitable, 'overzealous' judicial intervention to have consequences: Centre to SC

The vaccination strategy for Covid-19 has been formulated by the Centre in a "just, equitable, non-discriminatory" manner and any "overzealous" judicial intervention may result in unforeseen consequences, the government has told the Supreme Court.

In an affidavit filed by the Centre in response to the points raised by the top court, it said as vaccination of the entire country is not possible in one stretch due to the very suddenness of the pandemic, limited availability of vaccine doses and the vulnerability are the prime considerations.

The submission was made in a suo motu by the apex court case for ensuring essential supplies and services during the Covid-19 pandemic.

The top court has taken up issues such as the projected demand for oxygen in the country at present and in the near future, how the government intends to allocate it to "critically affected" states and its monitoring mechanism to ensure supply.

Also read: A new dilemma: What to do when Covid-19 vaccine supply exceeds demand?

The central government submitted that the vaccination policy conforms to the mandate of Article 14 and Article 21 of the Constitution and was made after several rounds of consultations and discussions with experts.

State governments and vaccine manufacturers require no interference by the top court as dealing with a pandemic of this magnitude, the Executive does have room for free play in the joints, in the larger public interest, it said.

"Any overzealous, though well-meaning judicial intervention may lead to unforeseen and unintended consequences in absence of any expert advice or administrative experience, leaving doctors, scientists, experts and executive very little room to find innovative solutions on the go," the Centre told the apex court in its 200-page affidavit.

It submitted that in the times of such grave and unprecedented crisis which the nation is fighting the disaster of an unprecedented magnitude, the executive functioning of the government needs the discretion to formulate policy in the larger interest.

"It is submitted that in view of the unprecedented and peculiar circumstances under which vaccination drive is devised as an executive policy, the wisdom of the executive should be trusted," it said.

Also read: Bharat Biotech commences direct supply of 'Covaxin' to 14 states

The government told the apex court that the price factor of vaccines will not have any impact on the ultimate beneficiary namely, the eligible person getting the vaccine since all state governments have already declared their policy decision that each State will be administering the vaccine to its residents, free of cost.

"Thus, while it is ensured that the two vaccine manufacturers are not unduly enriched from out of public money, the citizens are not supposed to make any payment for getting both doses of the vaccine," the Centre said.

The Centre said that the apex court in a plethora of judgements has laid down the parameters for judicial review of executive policies, which can only be struck down or interfered with on the grounds of manifest arbitrariness, allowing sufficient play in the joints to the executive, to function in accordance with its Constitutional mandate.

On the issue of invoking compulsory licensing of provisions under the Patents Act to ensure availability of vaccines and drugs, the government told the apex court that the main constraint is in availability of raw materials and essential inputs and therefore, any additional permissions and licenses may not result in increased production immediately.

The affidavit stated that the Ministry of Health is making all efforts to enhance the availability of antiviral drug Remdesivir through ramping up of production and sourcing through imports.

"However, in view of the current constraints on the availability of raw materials and other essential inputs, the mere addition of more production capacity may not lead to the desired outcomes of enhanced supplies," it said.

The Centre submitted that when there is a surge in cases and in demand of patented medicines/ drugs/ vaccines from all over the world the solution needs to be found out essentially at an executive level engaging at diplomatic levels.

"Any exercise of statutory powers either under the patents act 1970 read with Trips agreement and Doha declaration or in any other way can only prove to be counter-productive at this stage, the central government is very actively engaging itself with global organisations at a diplomatic level to find out a solution in the best possible interest of India," it said.